Oxadiazole compounds

US10562869B2 · kind B2 · utility

Assignee

• ReMYND N.V. · BE

Inventors

• Gerard Griffioen · Linden, BE
• Bart De Taeye · Kessel-Lo, BE
• Katrien Princen · Heverlee, BE
• Koen De Witte · Uccle - Ukkel, BE
• Emilie Blanche · Heverlee, BE
• Hasane Ratni · Habsheim, FR
• Matthias Nettekoven · Weil am Rhein, DE
• Mark Rogers-Evans · Bottmingen, CH

Key dates

• Filing date: Mar 17, 2015
• Grant date: Feb 18, 2020
• Expiry date: Mar 17, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/10
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1, R2, R3, L1, L2, L3, L4, L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.